{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:12:38Z","timestamp":1778026358264,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-026-04424-z","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:47:15Z","timestamp":1774576035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Twenty-four months progression-free survival (ongoing) for treatment of recurrent ovarian clear cell carcinoma with surufatinib in combination with toripalimab: a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Siyi","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boer","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"issue":"1","key":"4424_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","volume":"18","author":"T Li","year":"2025","unstructured":"Li T, Zhang H, Lian M, He Q, Lv M, Zhai L, et al. Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021. J Hematol Oncol. 2025;18(1):5.","journal-title":"J Hematol Oncol"},{"key":"4424_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.semcancer.2019.10.025","volume":"61","author":"S Khalique","year":"2020","unstructured":"Khalique S, Lord CJ, Banerjee S, Natrajan R. Translational genomics of ovarian clear cell carcinoma. Semin Cancer Biol. 2020;61:121\u2013131.","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"4424_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/ijgc-2022-003704","volume":"33","author":"J Stewart","year":"2023","unstructured":"Stewart J, Cunningham N, Banerjee S. New therapies for clear cell ovarian carcinoma. Int J Gynecol Cancer. 2023;33(3):385\u2013393.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"4424_CR4","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ygyno.2006.12.024","volume":"105","author":"DR Crotzer","year":"2007","unstructured":"Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007;105(2):404\u2013408.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"4424_CR5","first-page":"727","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY, Surufatinib. First Approval Drugs. 2021;81(6):727\u2013732.","journal-title":"First Approval Drugs"},{"issue":"18","key":"4424_CR6","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057\u20135069.","journal-title":"Cancer Res"},{"issue":"2","key":"4424_CR7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00432-021-03898-8","volume":"149","author":"Y Cao","year":"2023","unstructured":"Cao Y, Lu M, Sun Y, Gong J, Li J, Lu Z, et al. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial. J Cancer Res Clin Oncol. 2023;149(2):779\u2013789.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4424_CR8","doi-asserted-by":"publisher","first-page":"101171","DOI":"10.1016\/j.gore.2023.101171","volume":"46","author":"CA Calo","year":"2023","unstructured":"Calo CA, Levine MD, Brown MD, O\u2019Malley DM, Backes FJ. Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series. Gynecol Oncol Rep. 2023;46:101171.","journal-title":"Gynecol Oncol Rep"},{"issue":"10","key":"4424_CR9","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S1470-2045(24)00437-6","volume":"25","author":"Z Peng","year":"2024","unstructured":"Peng Z, Li H, Gao Y, Sun L, Jiang J, Xia B, et al. Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024;25(10):1288\u20131297.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4424_CR10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.6004\/jnccn.2022.0047","volume":"20","author":"DK Armstrong","year":"2022","unstructured":"Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, et al. NCCN guidelines\u00ae insights: Ovarian cancer, version 3.2022: Featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2022;20(9):972\u2013980.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"4424_CR11","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1525-1438.2007.01158.x","volume":"18","author":"M Takano","year":"2008","unstructured":"Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, et al. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer. 2008;18(5):937\u2013942.","journal-title":"Int J Gynecol Cancer"},{"key":"4424_CR12","doi-asserted-by":"crossref","unstructured":"Ye S, Fu Y, Liu S, Wang J, Zhou L, Jiang W et al. Surufatinib Combined With Toripalimab For The Treatment Of Recurrent Ovarian Clear Cell Carcinoma: Update Of A Prospective Single Center, Single-Arm Phase II Clinical Trial. Int J Gynecol Cancer. 2025;35(2).","DOI":"10.1016\/j.ijgc.2024.101019"},{"key":"4424_CR13","first-page":"A262","volume":"34","author":"S Ye","year":"2024","unstructured":"Ye S, Fu Y, Liu S, Wang J, Zhou L, Jiang W, et al. EV344\/#770\u2005 Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: a prospective single center, single-arm phase II clinical trial. Int J Gynecol Cancer. 2024;34:A262\u2013263.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"4424_CR14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s12094-020-02446-z","volume":"23","author":"A Gallego","year":"2021","unstructured":"Gallego A, Ramon-Patino J, Brenes J, Mendiola M, Berjon A, Casado G, et al. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma? Clin Transl Oncol. 2021;23(3):536\u2013542.","journal-title":"Clin Transl Oncol"},{"key":"4424_CR15","doi-asserted-by":"publisher","first-page":"5429","DOI":"10.2147\/OTT.S333029","volume":"14","author":"Y Li","year":"2021","unstructured":"Li Y, Liu W, Zhang X, Fang Y, Yue X, Zhang X, et al. Effective Disease Control After Combinatorial Treatment with a PD-1 Antibody and an mTOR Inhibitor for Recurrent Ovarian Clear Cell Carcinomas: A Case Report and Literature Review. Onco Targets Ther. 2021;14:5429\u20135434.","journal-title":"Onco Targets Ther"},{"key":"4424_CR16","doi-asserted-by":"publisher","first-page":"S783","DOI":"10.1016\/j.annonc.2022.07.649","volume":"33","author":"R Kristeleit","year":"2022","unstructured":"Kristeleit R, Clamp AR, Gourley C, Roux R, Hall M, Devlin MJ, et al. 521MO Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial. Ann Oncol. 2022;33:S783.","journal-title":"Ann Oncol"},{"issue":"18","key":"4424_CR17","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1158\/1078-0432.CCR-25-0201","volume":"31","author":"NYL Ngoi","year":"2025","unstructured":"Ngoi NYL, Choi CH, Zhu J, Lim D, Tan TZ, Sun H, et al. Durvalumab versus Physician\u2019s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. Clin Cancer Res. 2025;31(18):3907\u20133915.","journal-title":"Clin Cancer Res"},{"key":"4424_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ygyno.2024.03.027","volume":"186","author":"LT Gien","year":"2024","unstructured":"Gien LT, Enserro DM, Block MS, Waggoner S, Duska LR, Wahner-Hendrickson AE, et al. Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016. Gynecol Oncol. 2024;186:61\u201368.","journal-title":"Gynecol Oncol"},{"key":"4424_CR19","doi-asserted-by":"crossref","unstructured":"Dizon DS, Mathews CA, David SM, Machan JT, Hadfield MJ, Marks EI, et al. Final results of BrUOG 354: a randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. American Society of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500"},{"issue":"8Supplement","key":"4424_CR20","doi-asserted-by":"publisher","first-page":"CT162","DOI":"10.1158\/1538-7445.AM2023-CT162","volume":"83","author":"YK Chae","year":"2023","unstructured":"Chae YK, Ryan CW, Aung N, Robinson WR, Othus M, Sharon E, et al. Abstract CT162: a phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the clear cell ovarian, endometrial, cervical cancer cohorts. Cancer Res. 2023;83(8Supplement):CT162\u2013CT162.","journal-title":"Cancer Res"},{"key":"4424_CR21","doi-asserted-by":"crossref","unstructured":"Lee EK, Zhou Y, Wahner Hendrickson AE, Fleming GF, Krasner CN, Konstantinopoulos PA, et al. A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512). American Society of Clinical Oncology; 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.5515"},{"key":"4424_CR22","doi-asserted-by":"publisher","first-page":"114712","DOI":"10.1016\/j.biopha.2023.114712","volume":"162","author":"T Li","year":"2023","unstructured":"Li T, Wang X, Qin S, Chen B, Yi M, Zhou J. Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies. Biomed Pharmacother. 2023;162:114712.","journal-title":"Biomed Pharmacother"},{"key":"4424_CR23","doi-asserted-by":"crossref","unstructured":"Lin S, Gao M, Li J, Wang L, Lin Z-Q, Zhang B. A combination of niraparib plus anlotinib in patients with platinum-resistant ovarian clear cell carcinoma: Results of a single-arm phase II study (CC-ANNIE study). American Society of Clinical Oncology; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.e17552"},{"issue":"1","key":"4424_CR24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12885-022-09588-z","volume":"22","author":"S Ye","year":"2022","unstructured":"Ye S, Zhou S, Zhong S, Shan B, Jiang W, Yang W, et al. The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma. BMC Cancer. 2022;22(1):449.","journal-title":"BMC Cancer"},{"issue":"1","key":"4424_CR25","doi-asserted-by":"publisher","first-page":"2218104","DOI":"10.1080\/07853890.2023.2218104","volume":"55","author":"S Ye","year":"2023","unstructured":"Ye S, Zhou S, Wu Y, Pei X, Jiang W, Shi W, et al. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival. Ann Med. 2023;55(1):2218104.","journal-title":"Ann Med"},{"issue":"10","key":"4424_CR26","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1093\/nar\/gkae233","volume":"52","author":"A Bakr","year":"2024","unstructured":"Bakr A, Della Corte G, Veselinov O, Kelek\u00e7i S, Chen MM, Lin YY, et al. ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response. Nucleic Acids Res. 2024;52(10):5698\u20135719.","journal-title":"Nucleic Acids Res"},{"key":"4424_CR27","doi-asserted-by":"publisher","first-page":"952379","DOI":"10.3389\/fgene.2023.952379","volume":"14","author":"A Tong","year":"2023","unstructured":"Tong A, Di X, Zhao X, Liang X. Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics. Front Genet. 2023;14:952379.","journal-title":"Front Genet"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-026-04424-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04424-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-026-04424-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:37:17Z","timestamp":1778024237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12905-026-04424-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4424"],"URL":"https:\/\/doi.org\/10.1186\/s12905-026-04424-z","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Center. Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication and any accompanying images or clinical details was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"234"}}